TERNS PHARMACEUTICALS INC's ticker is TERN and the CUSIP is 880881107. A total of 104 filers reported holding TERNS PHARMACEUTICALS INC in Q4 2023. The put-call ratio across all filers is 0.27 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $1,377,990 | +3.8% | 202,348 | 0.0% | 0.29% | +40.5% |
| Q1 2024 | $1,327,403 | +1.1% | 202,348 | 0.0% | 0.20% | +0.5% |
| Q4 2023 | $1,313,239 | +29.0% | 202,348 | 0.0% | 0.20% | -34.6% |
| Q3 2023 | $1,017,810 | -42.5% | 202,348 | 0.0% | 0.31% | +0.3% |
| Q2 2023 | $1,770,545 | -26.1% | 202,348 | 0.0% | 0.31% | -37.2% |
| Q1 2023 | $2,395,800 | +16.3% | 202,348 | 0.0% | 0.50% | +11.7% |
| Q4 2022 | $2,059,903 | +21.0% | 202,348 | -30.0% | 0.44% | +11.6% |
| Q3 2022 | $1,703,000 | +137.5% | 289,068 | 0.0% | 0.40% | +107.9% |
| Q2 2022 | $717,000 | -16.5% | 289,068 | 0.0% | 0.19% | -11.6% |
| Q1 2022 | $859,000 | -58.0% | 289,068 | 0.0% | 0.22% | -45.6% |
| Q4 2021 | $2,044,000 | -32.1% | 289,068 | 0.0% | 0.40% | -16.1% |
| Q3 2021 | $3,012,000 | -15.0% | 289,068 | 0.0% | 0.47% | +8.2% |
| Q2 2021 | $3,544,000 | -67.6% | 289,068 | -41.9% | 0.44% | -78.4% |
| Q1 2021 | $10,946,000 | – | 497,555 | – | 2.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SUPERSTRING CAPITAL MANAGEMENT LP | 956,542 | $6,514,051 | 8.21% |
| Vivo Capital, LLC | 6,182,992 | $42,106,176 | 3.89% |
| Soleus Capital Management, L.P. | 4,947,738 | $33,694,096 | 2.97% |
| ACUTA CAPITAL PARTNERS, LLC | 369,280 | $2,514,797 | 2.12% |
| GREAT POINT PARTNERS LLC | 1,149,406 | $7,827,455 | 1.50% |
| VR Adviser, LLC | 3,410,058 | $23,222,495 | 1.48% |
| Octagon Capital Advisors LP | 1,364,400 | $9,291,564 | 1.46% |
| Deep Track Capital, LP | 6,100,000 | $41,541,000 | 1.24% |
| Orbimed Advisors | 7,619,135 | $51,886,309 | 1.02% |
| Worth Venture Partners, LLC | 17,470 | $118,971 | 0.88% |